| Gene Symbol | IGF2R |
| Protein Family | Mannose-6-phosphate receptor family |
| Protein Type | Receptor |
| Target Class | Receptor |
| Function | is a protein encoded by the IGF2R gene. |
| Mechanism of Action | Drugs targeting IGF2R typically work by blocking IGF2 binding and signaling through the IGF1R/IGF2R axis, thereby inhibiting mitogenic and anti-apoptotic effects in cancer cells. Alternatively, agents may enhance IGF2 clearance through IGF2R-mediated endocytosis to reduce circulating IGF2 levels and downstream signaling. |
| Primary Expression | neurons, astrocytes, and oligodendrocytes, where it participates in the regulation of IGF2 signaling and |
| Subcellular Localization | Cell membrane, endosomes, lysosomes |
| Druggability | Low (0.39) |
| Clinical Stage | Approved |
| Molecular Weight | 274 kDa |
| Amino Acids | 147 aa |
| Pathways | Lysosomal Enzyme Trafficking, Lysosomal function / degradation, Normal Growth and Development |
| UniProt ID | A0N9R6 |
| GeneCards | IGF2R |
| Human Protein Atlas | IGF2R |
| Associated Diseases | ALS, Aging, Alzheimer, Alzheimer's disease, Amyotrophic Lateral Sclerosis |
| Known Drugs/Compounds | Linsitinib (OSI-906), Figitumumab (CP-751,871), Ganitumab (AMG 479), MK-0646 (Dalotuzumab) |
| Interactions | RILP, SORT1, NEK7, Rb, PRDX3, RNF14 |
| SciDEX Target | View Target Profile (2 clinical trials) |
| SciDEX Hypotheses | Lysosomal Enzyme Trafficking Correction |
| KG Connections | 315 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |